Clinical Trial Update: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating individualized irinotecan dosing in FOLFIRI for first-line metastatic colorectal cancer based on UGT1A1 genetic polymorphism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI regimen (irinotecan + leucovorin + 5-fluorouracil)
• Irinotecan (often combined as FOLFIRI) (irinotecan)

Snippet

Sponsor: Centre Jean Perrin | Conditions: First Line Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED